Hepatic conversion of acetyl-CoA to acetate plays crucial roles in energy stress
Abstract
Accumulating evidence indicates that acetate is increased under energy stress conditions such as those that occur in diabetes mellitus and prolonged starvation. However, how and where acetate is produced and the nature of its biological significance are largely unknown. We observed overproduction of acetate to concentrations comparable to those of ketone bodies in patients and mice with diabetes or starvation. Mechanistically, ACOT12 and ACOT8 are dramatically upregulated in the liver to convert free fatty acid-derived acetyl-CoA to acetate and CoA. This conversion not only provides a large amount of acetate, which preferentially fuels the brain rather than muscle, but also recycles CoA, which is required for sustained fatty acid oxidation and ketogenesis. We suggest that acetate is an emerging novel ‘ketone body’ that may be used as a parameter to evaluate the progression of energy stress.
eLife assessment
This is important work that examines hepatic acetate production via ACOT12/18 in starvation and diabetes. The investigators use solid loss of function strategies in cells, including mouse primary hepatocytes, and in vivo mouse experiments to show that ACOTs are necessary for normal acetate production in the context of fasting and type 1 diabetes. Given that acetate is commonly thought to primarily represent a fermentation product, this study is of interest as it describes hepatic pathways converting fatty acids to acetate.
https://doi.org/10.7554/eLife.87419.3.sa0Introduction
Disordered homeostasis of energy metabolism, which is associated with emergency situations such as untreated diabetes mellitus, prolonged starvation, and ischemic heart/brain disease, is a serious threat to human health (Field et al., 2001; Galgani and Ravussin, 2008; Martinic and von Herrath, 2008; Must et al., 1999). In response to such disorder, the metabolic patterns of multiple organs have to be remodeled to rescue the imbalance and bring whole organism through the crisis (Denechaud et al., 2008; Frühbeck et al., 2001; Goldberg et al., 2018; Hirai et al., 2021; Meier and Gressner, 2004; Nishimoto et al., 2016; Palikaras et al., 2015; Russell and Cook, 1995). Ketone bodies, namely acetoacetate (AcAc), β-hydroxybutyrate (3-hydroxybutyrate, 3-HB), and acetone, are overproduced from fatty acids in the liver under conditions in which carbohydrate availability is reduced, such as diabetes and starvation. These bodies are released into blood and serve as a vital alternative metabolic fuel for extrahepatic tissues including the brain, skeletal muscle, and heart, where they are converted to acetyl-CoA and oxidized in the tricarboxylic cycle (TCA), providing a large amount of energy (Cahill, 2006; D’Acunzo et al., 2021; Dentin et al., 2006; Krishnakumar et al., 2008; Puchalska and Crawford, 2017; Robinson and Williamson, 1980).
Previous studies have shown that acetate concentrations are significantly increased in diabetes and prolonged starvation (Akanji et al., 1989; Seufert et al., 1984; Todesco et al., 1993), and acetate is considered to be a nutrient that nourishes the organism by undergoing conversion to acetyl-CoA which is further catabolized in the TCA (Lindsay and Setchell, 1976; Liu et al., 2018; Schug et al., 2015; Schug et al., 2016). Conversely, acetyl-CoA can also be hydrolyzed to acetate by proteins of the acyl-CoA thioesterase (ACOT) family (Swarbrick et al., 2014; Tillander et al., 2017). Unfortunately, it is not clear where, under what conditions and how acetate is produced, nor what is its biological significance. Considering that both acetate and ketone bodies are produced from acetyl-CoA and catabolized back to acetyl-CoA, we thoroughly investigated the production and utilization of acetate, also looking at ketone bodies as a comparison. We suggest that acetate is an emerging novel ‘ketone body’ that plays important roles, similar to those of classic ketone bodies, in energy stress conditions such as diabetes mellitus and prolonged starvation.
Note: our description of acetate as an emerging novel ‘ketone body’ does not suggest that it as a real ketone in structure, but emphasizes the high similarity of acetate and classic ketone bodies in terms of both the organ in which they are produced (liver), the substrate from which they are produced (fatty acids-derived acetyl-CoA), the roles they play as important sources of fuel and energy for many extrahepatic peripheral organs, their catabolism back to acetyl-CoA and degradation in the TCA cycle, and the physiological conditions of their production (under energy stresses such as prolonged starvation and untreated diabetes mellitus).
Results
Acetate is dramatically elevated under energy stress conditions in mammals
To investigate whether acetate is produced in a pattern similar to ketone bodies, we measured serum glucose, 3-beta-hydroxybutyrate (3HB), acetoacetate (AcAc), and other metabolites in 17 diabetes mellitus patients and 8 healthy volunteers as controls (Figure 1—figure supplement 1A; Figure 1—source data 1). We observed a significant increase of acetate in parallel with the canonical elevation of ketone bodies (3-HB and AcAc) and serum glucose in diabetes mellitus patients as compared with healthy controls (Figure 1A). We then detected acetate in mouse models and found that the levels of serum acetate and ketone bodies were dramatically elevated to the same extent in streptozotocin (STZ)-induced type I diabetic C57BL/6 (Figure 1B) and BALB/c mice (Figure 1—figure supplement 1B) as in type II diabetic db/db mice (Figure 1—figure supplement 1C). As expected, starvation also leads to a marked decrease in serum glucose concentration and an increase in serum acetate and ketone body levels in normal C57BL/6 (Figure 1C) and BALB/c mice (Figure 1—figure supplement 2). These data demonstrate that serum acetate is boosted to the same extent as canonical ketone bodies under energy stresses including those that occur with diabetes mellitus and starvation. For the sake of simplicity, we will refer to this acetate as 'energy stress-induced acetate (ES-acetate)'.

Acetate is produced at a levels comparable to those of ketone bodies in energy stress conditions.
(A) Enrichment of glucose, 3-HB, AcAc, and acetate in clinical serum samples from healthy volunteers and patients with diabetes mellitus (Healthy, n = 8; Diabetes, n = 17). (B) Enrichment of glucose, 3-HB, AcAc, and acetate in the serum of STZ-induced diabetic mice (C57BL/6, n = 5). (C) The levels of acetate, 3-HB, AcAc, and glucose in the serum of C57BL/6 mice (n = 5) starved for the indicated time course. Abbreviations: 3-HB, 3-hydroxybutyrate; AcAc, acetoacetate; NT, untreated control; STZ, streptozotocin. Values are expressed as mean ± standard deviation (SD) and analyzed statistically by two-tailed unpaired Student’s t-test (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n.s., no significant difference).
-
Figure 1—source data 1
Information describing the patient and healthy volunteers for the clinical data depicted in Figure 1.
- https://cdn.elifesciences.org/articles/87419/elife-87419-fig1-data1-v1.xlsx
ES-acetate is derived from free fatty acids in mammalian cells
Next, we asked which nutrients ES-acetate is derived from. In mammals, serum acetate generally has three sources: dietary acetate, as a metabolic product of gut microbiota, and as the intermediate of intracellular biochemical processes (Schug et al., 2016). As the mice used in this work were fed an acetate-free diet, we focused on acetate formed by gut microbiota and endogenous biochemical reactions. To determine whether gut microbiota contribute to the production of ES-acetate, mice were pre-treated with antibiotics to eliminate gut microbes (saline as control) as reported previously (Sivan et al., 2015). We observed that antibiotic pre-treatment failed to obviously affect the production of acetate that was induced by either starvation (Figure 2—figure supplement 1A, B) or diabetes (Figure 2—figure supplement 1C), demonstrating that ES-acetate is mainly produced endogenously. Next we used nuclear magnetic resonance (NMR) (Figure 2—figure supplement 2A, B) and gas chromatography–mass spectrometry (GC–MS) (Figure 2—figure supplement 2C, D) to detect the acetate that was secreted into the culture medium by several cell lines, and found that these cells showed different ability in producing acetate. Consistently, Liu et al., 2018 reported that acetate is derived from glucose in mammalian cells supplied with abundant nutrients. Indeed, we observed the secretion of different amounts of U-13C-acetate after cells were cultured in medium supplemented with U-13C-glucose (Figure 2—figure supplement 3A). Interestingly, we also observed the production of 36.6% of non-U-13C-acetate, indicating that this proportion of acetate is derived from nutrients other than glucose (Figure 2—figure supplement 3B).
We then examined whether the acetate secreted by cultured cells is derived from amino acids (AAs) and free fatty acids (FFAs) upon starvation. After different cells were cultured in Hanks’ balanced salt solutions (HBSS, free of glucose, fatty acids and amino acids) supplemented with FFAs or amino acids for 20 hr, supplementation with FFAs (Figure 2—figure supplement 4D, E) rather than amino acids (Figure 2—figure supplement 4A–C) significantly increased acetate levels, suggesting a major contribution of FFAs to acetate production. To confirm this observation, a series of widely used cell lines and mouse primary hepatocytes (MPHs) were cultured in HBSS supplemented with U-13C-palmitate, before secreted U-13C-acetate was measured (Figure 2A). These cell lines displayed quite different abilities to convert palmitate to acetate, and were accordingly divided into FFA-derived acetate-producing cells (FDAPCs: LO2, MPH, AML12, etc.) and no-FFA-derived acetate-producing cells (NFDAPCs: HEK-293T, Huh7, etc.). All of the FDAPCs secreted U-13C-acetate in a manner that was dependent on the dose of U-13C-palmitate supplementation (Figure 2B–D). We also observed that high-fat diet induced a significant increase in acetate production in both normal and STZ-induced diabetic mice (Figure 2E). Taken together, these findings suggest that acetate can be derived from FFAs in energy stress conditions.

Acetate is derived from free fatty acids (FFAs) in mammalian cells.
(A) The amount of U-13C-acetate secreted by the indicated cell lines cultured in U-13C-palmitate-containing Hanks’ balanced salt solution (HBSS) for 20 hr (n = 3). (B–D) The amount of U-13C-acetate secreted by MPH (B), LO2 (C), and AML12 (D) cells cultured in HBSS supplemented with increasing doses of U-13C-palmitate for 20 hr (n = 3). (E) Enrichment of acetate in the serum of untreated or STZ-induced diabetic C57BL/6 mice (n = 10) fed with a high-fat diet (HFD) or a control diet. Abbreviations: MPH, mouse primary hepatocyte; STZ, streptozotocin; UD, undetectable. Values are expressed as mean ± standard deviation (SD) and were analyzed statistically using a two-tailed unpaired Student’s t-test (A, E) or one-way analysis of variance (ANOVA) (B–D) (*p < 0.05, ****p < 0.0001, n.s., no significant difference).
ACOT12 and ACOT8 are involved in acetate production in mammalian cells
It has been reported that acyl-CoAs with different lengths of carbon chain could be hydrolyzed to FFAs specifically by a corresponding ACOTs family protein (Tillander et al., 2017). Acetyl-CoA, the shortest chain of acyl-CoA and the critical product of β-oxidation, is hydrolyzed to acetate by acyl-CoA thioesterase 12 (ACOT12) (Swarbrick et al., 2014). We next analyzed the GEO database and found out that the expression of Acot1/2/8/12 is upregulated significantly alongside the increase of β-oxidation and ketogenesis in mice liver after 24 hr of fasting (Figure 3A; Figure 3—figure supplement 1A). To determine which ACOT is responsible for ES-acetate production, we overexpressed a series of ACOTs in HEK-293T cells and observed large amount of acetate production when either ACOT8 or ACOT12 was overexpressed (Figure 3B), indicating that these two ACOTs are involved in ES-acetate production. Consistently, the protein levels of both Acot12 and Acot8 are upregulated robustly in the livers of either starved mice or STZ-induced type I diabetic mice (Figure 3—figure supplement 1B, C). Furthermore, when ACOT12 and ACOT8 were separately overexpressed in NFDAPCs HEK-293T and Huh7, FFA-derived acetate was significantly increased (Figure 3—figure supplement 1D, E). Similarly, overexpression of wildtype ACOT12 and ACOT8, rather than their enzyme activity-dead mutants, in HEK-293T (Figure 3C) and Huh7 (Figure 3D) cells drastically increased the production of U-13C-acetate derived from U-13C-palmitate (Ishizuka et al., 2004; Swarbrick et al., 2014). By contrast, knockdown (KD) of ACOT12 or ACOT8 in FDAPCs MPH (Figure 3E, F) and LO2 (Figure 3—figure supplement 1F, G) diminished U-13C-acetate production. These data reveal that ACOT12 and ACOT8 are responsible for ES-acetate production.

ACOT12 and ACOT8 are involved in acetate production in mammalian cells.
(A) Heatmap showing the differential hepatic expression of genes in the fed and fasted groups. RNAseq analysis data from Goldstein et al., 2017. (B) The secretion of acetate (upper panel) by HEK-239T cell lines overexpressing various ACOTs, and the protein levels of expressed ACOTs (lower panel). (C,D) HEK-293T (C) and Huh7 (D) cell lines overexpressing control vector, wildtype (WT) ACOT12 and ACOT8 or enzyme activity-dead mutants (Mut) of these two enzymes were cultured in Hanks’ balanced salt solution (HBSS) containing U-13C-palmitate for 20 hr, before U-13C-acetate was detected. (E, F) U-13C-acetate secreted by Acot12- or Acot8-knockdown mouse primary hepatocytes (MPH) after incubation in U-13C-palmitate-containing HBSS for 20 hr. Abbreviations: ACOT8 Mut, ACOT8 H78A mutant; ACOT12 Mut, ACOT12 R312E mutant; shAcot8, short hairpin RNA targeting mouse Acot8 gene; shAcot12, short hairpin RNA targeting mouse Acot12 gene; UD, undetectable. Values are expressed as mean ± standard deviation (SD) (n = 3) of three independent experiments and analyzed using unpaired Student’s t-tests (**p < 0.01, ***p < 0.001, ****p < 0.0001, n.s., no significant difference).
-
Figure 3—source data 1
Complete, unedited immunoblots, as well as immunoblots including sample and band identification, are provided for the immunoblots presented in Figure 3.
- https://cdn.elifesciences.org/articles/87419/elife-87419-fig3-data1-v1.zip
Hepatic ACOT12 and ACOT8 are responsible for ES-acetate production in energy stress conditions
Next we were prompted to determine which organ and subcellular structures are mainly involved in the generation of ES-acetate. First, we analyzed the expression of ACOTs individually at mRNA level in various tissues of human and mice by employing the GTEx and GEO databases. ACOT12 is mainly expressed in human liver together with genes encoding ketogenic enzymes (HMGCS2, HMGCSL, ACAT1, and BDH1), whereas ACOT8 is expressed ubiquitously at a relative high level in most tissues (Figure 4—figure supplement 1). Acot12 is also expressed mainly in mouse liver and kidney, whereas Acot8 seems to be expressed at a much lower level in nearly all of the mouse tissues examined (Figure 4—figure supplement 2A). Differing from their mRNA expression patterns in the GEO database, we observed high levels of both Acot12 and Acot8 proteins in mouse liver and kidney (Figure 4—figure supplement 2B). Consistently, adenovirus-mediated liver-targeted knockdown of either Acot12 or Acot8 dramatically abolished acetate production by starved or diabetic C57BL/6 mice (Figure 4A–F), and conditional deletion of Acot12 or Acot8 in liver dramatically decreased acetate production in starved mice (Figure 4G–J), demonstrating that the liver is the main organ responsible for ES-acetate production. Moreover, U-13C-acetate derived from U-13C-palmitate in glucose-free HBSS was diminished by replenishment of glucose (Figure 4—figure supplement 3), in accordance with the concept that glucose is preferable to fatty acids as an energy source. These observations demonstrate that hepatic ACOT12 and ACOT8 are induced and responsible for ES-acetate production in diabetes mellitus and during starvation.

ACOT12 and ACOT8 are responsible for acetate production in energy stress conditions.
(A, C) Acot12 in mice (C57BL/6) liver was knocked down by adenovirus-based shRNA, followed by detection of Acot12 protein with Western Blot (A) and evaluation of knockdown efficiency by calculating Acot12 level relative to β-actin (C). (B, D) The knockdown efficiency of Acot8 was determined in the same way as that of Acot12. (E) Enrichment of serum acetate in normal diet and 16 hr fasted mice (C57BL/6) with adenovirus-mediated knockdown of Acot12 or Acot8 in the liver. (F) Enrichment of serum acetate in streptozotocin (STZ)-induced diabetic mice (C57BL/6) with adenovirus-mediated knockdown of Acot12 or Acot8 in the liver. (G, H) Acot12 (G) or Acot8 (H) was conditionally deleted in the liver of mice (C57BL/6) by Cre-Loxp in liver, followed by detection of Acot12 and Acot8 protein with Western Blot. (I, J) Enrichment of serum acetate in normal diet and 16 hr fasted mice (C57BL/6) with Cre-Loxp-mediated conditional deletion of Acot12 (I) or Acot8 (J) in liver. Results are expressed as mean ± standard deviation (SD) of three independent experiments in (C, D), n = 10 mice per group in (E, F) and n = 6 mice per group in (I, J). Results were analyzed by unpaired Student’s t-tests (**p < 0.01, ***p < 0.001, ****p < 0.0001, n.s., no significant difference).
-
Figure 4—source data 1
Complete, unedited immunoblots, as well as immunoblots including sample and band identification, are provided for the immunoblots presented in Figure 4.
- https://cdn.elifesciences.org/articles/87419/elife-87419-fig4-data1-v1.zip
ACOT12- and ACOT8-catalyzed acetate production is dependent on the oxidation of FFA in both mitochondria and peroxisomes
When next made efforts to identify the subcellular domains in which acetate is produced. Immunofluorescence staining and cell fractionation showed that ACOT12 was largely localized in cytosol and ACOT8 mainly in peroxisome (Figure 5A, B). It is well known that fatty acids of different chain lengths can be oxidized to yield acetyl-CoA in either the mitochondria or peroxisomes of hepatocytes, and that mitochondrial acetyl-CoA produced in fatty acid oxidation (FAO) is often exported to the cytosol in the form of citrate, which is further cleaved back to acetyl-CoA by ATP citrate lyase (ACLY) (Figure 5H; Lazarow, 1978; Leighton et al., 1989; Lodhi and Semenkovich, 2014). Thus, we examined acetate production after mitochondria- or peroxisome-yielded acetyl-CoA had been blocked. Knockdown or etomoxir inhibition of carnitine palmitoyltransferase 1 (CPT1), the main mitochondrial fatty acids transporter, decreased more than one-half of U-13C-palmitate-derived U-13C-acetate production in LO2 cell lines, despite mitochondrial β-oxidation being almost completely abolished (Figure 5C–E). Similarly, knockdown of ACLY diminished palmitate-derived acetate production to the same extent as CPT1 KD (Figure 5F). We then knocked down ATP-binding cassette subfamily D member 1 (ABCD1), a peroxisome fatty acids transporter, and observed a less than one-half decline in the production of 13C-palmitate-derived U-13C-acetate (Figure 5G). These results, together with the localization of ACOT12 and ACOT8, suggest that acetyl-CoA produced in FAO in the mitochondria and peroxisome is converted to acetate in the cytosol by ACOT12 and in peroxisomes by ACOT8 (Figure 5H).

Acetate production is dependent on the oxidation of free fatty acids (FFAs) in both mitochondria and peroxisomes.
(A) Co-immunostaining of Flag-ACOT8 with the peroxisome marker catalase and of Flag-ACOT12 with the cytosol marker GAPDH in LO2 cells. Nuclei were stained with DAPI. Scale bars represent 10 μm. (B) The protein levels of Acot12 and Acot8 in the subcellular fractions of mouse primary hepatocyte (MPH) cells. Abbreviations: ER, endoplasmic reticulum; Lyso, lysosome; Mito, mitochondria; Perox, peroxisome. (C, D) U-13C-acetate production (C) and the relative β-oxidation rate (D) in carnitine palmitoyltransferase 1A (CPT1A)-knockdown LO2 cells cultured in Hanks’ balanced salt solution (HBSS) containing U-13C-palmitate for 20 hr. (E) U-13C-acetate production (left) and the relative β-oxidation rate (right) of LO2 cells cultured in U-13C-palmitate-containing HBSS with or without the CPT1 inhibitor etomoxir (20 μM) for 20 hr. (F) U-13C-acetate production in ATP citrate lyase (ACLY)-knockdown LO2 cells cultured in HBSS supplemented with U-13C-palmitate for 20 hr. (G) U-13C-acetate production in ATP-binding cassette subfamily D member 1 (ABCD1)-knockdown LO2 cells cultured in HBSS containing U-13C-palmitate for 20 hr. (H) A schematic diagram depicting the mitochondrial and peroxisome pathways of acetate production via the oxidation of FFAs in hepatocytes. Very long- and long-chain fatty acids (VL/LCFAs) are transported through ABCD1 into a peroxisome, where they are further degraded into medium-chain fatty acids (MCFAs) via the fatty acid oxidation (FAO) process. This process involves the production of acetyl-CoA, which is further converted to acetate by peroxisome-localized ACOT8. MCFAs generated in peroxisomes are exported into the cytosol and absorbed directly by mitochondria. Cytosolic acyl-CoA derived from medium- and long-chain fatty acids (M/LCFAs) is transferred into mitochondria through CPT1A. All of the fatty acids and acyl-CoA in mitochondria undergo FAO to be degraded to acetyl-CoA. Then, acetyl-CoA together with oxaloacetate is synthesized to form citrate in the tricarboxylic cycle (TCA). Citrate is subsequently exported into the cytosol, where it is lysed to acetyl-CoA by ACLY. Acetyl-CoA is finally converted to acetate by cytosol-localized ACOT12. Values in (C–G) are expressed as the mean ± standard deviation (SD) (n = 3) of three independent measurements. **p < 0.01, ***p < 0.001, ****p < 0.0001 by two-tailed unpaired Student’s t-tests.
-
Figure 5—source data 1
Complete, unprocessed immunoblots displaying sample and band identification are presented in Figure 5, along with the corresponding raw data for immunostaining.
- https://cdn.elifesciences.org/articles/87419/elife-87419-fig5-data1-v1.zip
ACOT12- and ACOT8-catalyzed recycling of CoA from acetyl-CoA is crucial for sustainable FAO
Subsequently, we tried to explore the biological significance of ES-acetate production in response to energy stress by detecting a series of serum metabolic parameters. Knockdown of Acot12 or Acot8 failed to alter the levels of blood glucose as well as insulin in fasted and non-fasted mice, implying that these two molecules may not be involved in glucose metabolism (Figure 6—figure supplement 1A–C). However, knockdown of these enzymes caused significant accumulation of total FFAs and various saturated or unsaturated fatty acids, whereas triacylglycerol (TG) levels were not altered (Figure 6—figure supplement 1D–J). Considering that in diabetes and after prolonged starvation mobilized lipid is mainly transported in the form of plasma albumin-bound fatty acids, rather than TG, these results suggest that ACOT12 and ACOT8 might be required for rapid degradation of fatty acids in these cases. Indeed, we detected attenuated FAO in ACOT12 and ACOT8 knockdown MPH and LO2 cells (Figure 6A, B; Figure 6—figure supplement 1K, L). We were then prompted to identify the mechanism underlying such attenuation of FAO. A clue is the knowledge that reduced free Coenzyme A (CoA) is a crucial coenzyme for many metabolic reactions, including those involved in oxidative degradation of fatty acid. Maintenance of the balance between the reduced CoA pool and the oxidized CoA pool is definitely important for sustaining those reactions (Sivanand et al., 2018). We wanted to know whether ACOT12- and ACOT8-catalyzed conversion of acetyl-CoA to free CoA plays a key role in maintaining both free CoA level and the balance between reduced CoA and oxidized CoA. To our surprise, in Acot12 or Acot8 KD MPHs, the level of reduced CoA was decreased by 75.2% and 68.3%, respectively; acetyl-CoA increased by 3.49- and 1.71-fold, respectively; and the ratios of reduced CoA to acetyl-CoA declined from 7.62 to 0.41 and 0.89, respectively (Figure 6C–E). In accordance with such alterations, concentrations of other oxidized CoAs (octanoyl-CoA, caproyl-CoA, and succinyl-CoA), whose generation requires adequate levels of reduced CoA as coenzyme, were diminished (Figure 6—figure supplement 2A–C). By contrast, metabolites (acetoacetyl-CoA, cholesterol [CHOL], high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C]) that have acetyl-CoA as the direct substrate for their synthesis were markedly increased (Figure 6—figure supplement 2D–G). It is important to point out that among all of the oxidized CoA compounds examined, the level of acetyl-CoA is far higher than than that of the other molecules, and the switch between acetyl-CoA and reduced CoA plays a significant role in the regulation of CoA pool balance (Figure 6F; Figure 6—figure supplement 2H). This observation explains why ACOT12- and ACOT8-catalyzed hydrolysis of acetyl-CoA to free CoA and acetate is the crucial step in the maintenance of reduced CoA level and sustained FAO.

ACOT12 and ACOT8 serve to maintain the CoA pool for sustained fatty acid oxidation (FAO).
(A, B) Mouse primary hepatocytes (MPHs) knocked down for Acot12 (A) or Acot8 (B) were cultured in glucose-free reaction buffer containing 0.8 μCi/ml [9,10-3H(N)]-oleic acid for 20 hr, before the relative β-oxidation rate was determined. (C) Relative abundance (M + 0) of reduced CoA in MPHs knocked down for Acot12 or Acot8. (D) Relative abundance (M + 0) of acetyl-CoA in MPHs knocked down for Acot12 or Acot8. (E) The ratio of reduced CoA to acetyl-CoA in MPHs knocked down for Acot12 or Acot8. (F) Relative abundance (M + 0) of reduced CoA and various oxidized CoA compounds in MPHs. Abbreviations: Ac-CoA, acetyl-CoA; HMG-CoA, 3-hydroxy-3-methylglutaryl-CoA. Values are expressed as mean ± standard deviation (SD) (n = 3) of three independent experiments and were analyzed using unpaired Student’s t-tests (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n.s., no significant difference).
Hydrolysis of acetyl-CoA by ACOT12 and ACOT8 is beneficial to ketogenesis
Distinct from other oxidized CoA compounds, HMG-CoA, a key intermediate for the synthesis of ketone bodies using acetyl-CoA as a substrate, was dramatically reduced in Acot12 and Acot8 KD MPHs, demonstrating that Acot12 and Acot8 may be positive regulators of HMG-CoA level (Figure 7A). Accordingly, the main ketone bodies AcAc and 3-HB were decreased significantly in STZ-induced diabetic mice with knockdown of Acot12 or Acot8 (Figure 7B, C). To clarify the mechanism that underlies ACOT12/8 regulation of HMG-CoA, we detected the protein level of 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2), the key enzyme for HMG-CoA synthesis. Interestingly, Hmgcs2 was remarkably downregulated in Acot12/8 KD MPHs (Figure 7D–G), indicating that Acot12 and Acot8 are positive regulators of Hmgcs2 protein level. A previous study showed that HMGCS2 activity is suppressed by acetylation (Wang et al., 2019). Thus, we examined the acetylation of Hmgcs2 and observed a clear increase in Hmgcs2 acetylation in Acot12/8 KD MPHs (Figure 7H), corresponding to the increase in acetyl-CoA level (Figure 6D), the direct substrate of acetylation. This observation demonstrates that ACOT12 and ACOT8 are also positive regulators of HMGCS2 activity by hydrolyzing acetyl-CoA to avoid accumulation of acetyl-CoA and over-acetylation of HMGCS2. Taken together, these results suggest that ACOT12 and ACOT8 are upregulated upon energy stress, and in turn enhance the function of HMGCS2 by increasing not only its concentration but also its activity, facilitating the production of ketone bodies to fuel the extrahepatic tissues.

ACOT12 and ACOT8 are required for the production of ketone bodies in streptozotocin (STZ)-induced diabetes.
(A) Relative abundance (M + 0) of HMG-CoA in mouse primary hepatocytes (MPHs) knocked down for Acot12 or Acot8 (n = 3). (B, C) Serum levels of acetoacetate (AcAc) (B) and 3-hydroxybutyrate (3-HB) (C) in STZ-induced diabetic C57BL/6 mice with adenovirus-mediated knockdown of Acot12 or Acot8 in the liver. (D, E) The protein levels of Hmgcs2 in MPHs knocked down for Acot12 (D) and Acot8 (E). (F, G) Acot12 (F) and Acot8 (G) in mice (C57BL/6) liver were knocked down by adenovirus-based shRNA, before Hmgcs2 protein was detected by Western Blot. (H) Western Blot (upper panel) and evaluation of the relative acetylation (Ac-Lys) level by calculating the ratio of acetylated Hmgcs2 relative to Hmgcs2 (lower panel). Abbreviations: HMG-CoA, 3-hydroxy-3-methylglutaryl-CoA; Hmgcs2, 3-hydroxy-3-methylglutaryl-CoA synthase 2. Results are expressed as the mean ± standard deviation (SD) of three independent experiments in (A) and n = 10 mice per group in (B, C), and were analyzed by using unpaired Student’s t-tests (*p < 0.05, **p < 0.01, ****p < 0.0001, n.s., no significant difference).
-
Figure 7—source data 1
Complete, unedited immunoblots, as well as immunoblots including sample and band identification, are provided for the immunoblots presented in Figure 7.
- https://cdn.elifesciences.org/articles/87419/elife-87419-fig7-data1-v1.zip
Acetate is beneficial to extrahepatic tissues during energy stress
Many studies have shown that the ketone bodies are produced mainly in the liver in diabetes mellitus and prolonged starvation, providing fuel for crucial extrahepatic organs such as the brain (Puchalska and Crawford, 2017; Robinson and Williamson, 1980). Given that acetate has also been reported to serve as an energy substance for cells (Comerford et al., 2014; Mashimo et al., 2014; Schug et al., 2016), we wanted to know whether ES-acetate plays the same role as ketone bodies in the same emergency status. 2-13C-acetate was injected into starved or STZ-induced diabetic mice intraperitoneally, before 13C-labeled metabolic intermediates were analyzed by liquid chromatography–mass spectrometry (LC–MS). 13C-acetyl-CoA and 13C-incorporated TCA cycle metabolites such as citrate, aconitate, isocitrate, succinate, fumarate, and malate were dramatically increased in the brain (Figure 8A–G), but decreased in muscle (Figure 8—figure supplement 1), of starved or diabetic mice as compared with untreated control mice. This is in line with the notion that the brain has priority in energy expenditure in animals experiencing energy stresses. Moreover, we performed intraperitoneal injection of both acetate and 3-HB simultaneously in fasting mice and compared the serum concentration curves for these compounds. Interestingly, acetate not only took less time to reach peak plasma level than 3-HB (5 vs 12 min), but also much less time to be eliminated (20 vs 120 min), implying that, as previously reported (Sakakibara et al., 2009), acetate may be more rapidly absorbed and consumed than 3-HB by the extrahepatic organs of mice (Figure 8H). These results suggest that acetate is an emerging novel ‘ketone body’ produced in liver from FFA and functioning to fuel extrahepatic organs, in particular brain, in the emergency status such as energy stresses. the brain, in the emergency status such as energy stresses. when in an emergency status such as energy stress.
Next, we examined the physiological significance of ES-acetate to the behaviors of animals under energy stress. We performed a list of behavioral tests: forelimb grip force test to assess forelimb muscle strength, a rotarod test to examine neuromuscular coordination, an elevated plus maze test (EPMT) to assess anxiety-related behavior, a Y-maze test (YMZT), and a novel object recognition (NOR) test to evaluate working memory and cognitive functions. It is clear that the forelimb strength and running time in the rotarod test were dramatically reduced in diabetic mice, further reduced by knockdown of Acot12 or Acot8, and rescued by administration of exogenous acetate (Figure 8—figure supplement 2A, B). Interestingly, the parameters related to muscle force and movement ability in other tests—including total distance in YMZT, total entries in YMZT and total distance in the NOR test—were also decreased in diabetic mice and further worsened by knockdown of Acot12 or Acot8 (Figure 8—figure supplement 2E, F, H). These observations demonstrate that ES-acetate is important for muscle force and neuromuscular coordinated movement ability. The EPMT test, correct alteration in YMZT, and object recognition index in the NOR test showed no significant difference among normal mice, diabetic mice, and Acot12/8 KD mice (Figure 8—figure supplement 2C, D, G), indicating that psychiatric abilities, memory, and cognitive behaviors are not markedly influenced by Acot12/8 KD in the early stage of diabetes mellitus. This is possibly because the brain exhibits the greatest flexibility among all extrahepatic tissues under energy stress in utilizing all available energy sources, including glucose, ketone bodies and acetate.

Brain exhibits increased acetate consumption during energy stress.
(A–G) Relative abundances (M + 1) of 13C-acetyl-CoA (A), 13C-citrate (B), 13C-aconitate (C), 13C-isocitrate (D), 13C-succinate (E), 13C-fumarate (F), and 13C-malate (G) in the brain of starved or diabetic mice (C57BL/6) were determined 1 hr after intraperitoneal injection of 2-13C-acetate (310 mg/kg). (H) The abundance of acetate and 3-hydroxybutyrate (3-HB) in the serum of fasting mice (C57BL/6) after intraperitoneal injection (acetate 300 mg/kg, 3-HB 520 mg/kg). (I) A working model describing the biological significance of ACOT12- and ACOT8-catalized conversion of acetyl-CoA to acetate and CoA. Under energy stress conditions, such as in diabetes mellitus and after prolonged starvation, at least two advantages are obtained by converting acetyl-CoA to acetate and CoA: (1) CoA is required for sustained fatty acid oxidation (FAO) and for the production of ketone bodies in the liver; (2) acetate serves as a novel ketone body to fuel extrahepatic tissues, particularly the brain. Values in (A–H) are expressed as the mean ± standard deviation (SD) (n = 5 mice per group in A–G and n = 7 mice per group in H) and were analyzed statistically by employing unpaired Student’s t-tests (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n.s., no significant difference).
Discussion
It is well known that glucose and ketone bodies are the main fuels for the brain in different physiological conditions. In normal conditions, the brain uses glucose as the main energy source. By contrast, it utilizes ketone bodies as an important energy source when in an energy stress status, such as diabetes mellitus or prolonged starvation, because in these cases body glucose stores have already been already exhausted and gluconeogenesis cannot provide sufficient glucose. As a result, sustained mobilization of stored lipid and the resultant production of ketone bodies from FAO are crucial for nourishing extrahepatic tissues, in particular the brain in energy stress conditions. However, sustained FAO in hepatocytes requires the rapid recycling of free CoA, which is the crucial co-enzyme for FAO. Our study elucidates that this requirement is satisfied by ACOT12- and ACOT8-catalized conversion of acetyl-CoA to acetate and CoA. It is important to point out that the significance of ACOT12- and ACOT8-catalyzed recycling of free CoA for FAO is analogous to that of lactate dehydrogenase-catalyzed recycling of NAD+ for glycolysis (Castro et al., 2009; Cerdán et al., 2006). In addition to providing CoA, this reaction also provide acetate that serves as an energy source to fuel extrahepatic tissues (Figure 8I). As an alternative fuel in emergency status, acetate may be preferred by the brain because it is directly converted to acetyl-CoA by acetyl-CoA synthetase (ACSS), and is undoubtedly more convenient than acetoacetate and 3-HB, which need two and three enzyme-catalyzed steps, respectively, to be converted to acetyl-CoA. In this regard, we consider acetate as an emerging novel ‘ketone body’, and recommend that its blood level should be detected, together with those of classic ketone bodies, to indicate the status of FAO in liver and of lipid mobilization in adipose tissue upon energy stress.
In summary, this study clarified where and how acetate is produced in energy stress conditions and identifies the profound biological significance of acetate production catalyzed by ACOT12 and ACOT8. More importantly, we suggest that acetate is an emerging novel ‘ketone body’ and may be used as a parameter to evaluate the progression of energy stress in the future.
Materials and methods
Collection of clinical samples
Request a detailed protocolHuman clinical serum samples were collected with the ethical approval of the clinical research ethics committee of The First Affiliated Hospital of Xiamen University (Xiamen, Fujian, China). Information describing the patients (diagnosed with type II diabetes) and healthy volunteers is provided in Figure 1—source data 1. The serum samples were stored in a −80°C refrigerator and were mainly obtained from The First Affiliated Hospital of Xiamen University (China) after obtaining informed consent.
Animal studies
Request a detailed protocolAll animal studies were approved by the Animal Ethics Committee of Xiamen University (China) (acceptance no: XMULAC20190166). BALB/c and C57BL/6 mice (6–7 weeks, random sex, in groups) were obtained from Xiamen University Laboratory Animal Center (China). C57BLKS/J-LepRdb/LepRdb (db/db) mice were purchased from GemPharmatech Co, Ltd (China). All animals were kept in SPF conditions with 12 hr light–dark cycle, free chow and water accessed to standard rodent diet in accordance with institutional guidelines. For STZ-induced diabetic models (Gonzalez et al., 2003; Like and Rossini, 1976), mice were randomized and fasted for 12 hr but water was allowed before intraperitoneal injection of STZ (a single high dose of 150 mg/kg). Note that BALB/c diabetic mice induced by STZ needed to be fed with a 60 kcal% fat diet (high fat diet, HFD) for acetate detection until the end of the experiment. For the animal starvation experiment, mice were fasted but water was allowed. For the antibiotic treatment experiment, mice were treated with a mixture of antibiotics including 1 mg/ml ampicillin, 5 mg/ml streptomycin, and 1 mg/ml colistin in sterile drinking water for 3 weeks before STZ injection or a starvation experiment, and treatment was continued to the end of experiment (Vétizou et al., 2015). Cre-Loxp-mediated liver-specific Acot12 or Acot8 knockout mice (Acot12−/− or Acot8−/−), C57BL/6JGpt-Acot12em1Cflox/Gpt and C57BL/6JGpt-Acot8em1Cflox/Gpt mice were purchased from GemPharmatech Co, Ltd (China). Acot12 Flox/Flox or Acot8 Flox/Flox mice crossed with Alb-Cre mice (C57BL/6), confirmed the efficient deletion of Acot12 or Acot8 specifically in the liver (6–7 weeks, random sex, in groups). For adenovirus-mediated liver-specific RNAi mouse models, injection of 200 μl adenovirus (titer: 1012) via the tail vein was performed in C57BL/6 mice (6–7 weeks, random sex, in groups) and knockdown efficiency in the liver was determined by Western Blot 2 months after the injection. Adenoviruses were propagated in QBI-293A cells and purified by cesium chloride density gradient ultracentrifugation. For all animal models, blood was collected from the tail vein, followed by detection of glucose with a Roche glucometer and other serum components with NMR and MS. Mouse tissue samples were collected at the end of experiment for Western Blot.
Animal behavior analysis
Request a detailed protocolBehavior analysis was performed by using age-matched C57BL/6 mice (4 months, random sex, in groups). Diabetes mellitus was induced by STZ in normal or adenovirus-mediated liver-specific RNAi mice. Mice were moved to the experimental room 1 hr before starting the experiment. All objects or pieces of apparatus were thoroughly cleaned with 75% alcohol between trials to remove odors. All mice exhibited excellent health throughout the study period.
For the forelimb grip force test, the forelimb grip forces were measured using a Grip Strength Meter (Ugo Basile, Italy) and the peak force was defined as the average of three successive measurements. The rotarod test was performed using a progressive acceleration setting from 5 to 40 rpm for 2 min using a five-lane apparatus (Ugo Basile, Italy). Before the rotarod test, all mice were trained at 5 rpm for 2 min daily for 2 days. For acetate-rescuing experiments, the forelimb grip force test and rotarod test were conducted after 5 min of intraperitoneal injection of acetate.
The Elevated Plus Maze Test (EPMT) was performed with a maze of 40 cm in length, 10 cm in width, and 50 cm in height (Panlad, Spain), which consists of four elevated arms radiating from a central platform, forming a plus shape. Two of the opposed arms were enclosed by a wall of 20 cm in height. Each mouse was placed in the same area, and then left to explore the maze for 5 min. The amount of time spent in the open and closed arms was measured with a video-imaging system (Dazzle DVC100 Video). Data analyses were performed using active-monitoring software (smart3.0). The Y-Maze Test (YMZT) was carried out using a Y-shaped maze with three light-colored, opaque arms (30 cm in length, 6 cm in width, and 5 cm in height; Panlad, Spain) orientated at 120 angles from each other. Each mouse was placed in the same area, and then left to explore the maze for 5 min. The number of entries into the arms and alterations were recorded with a video-imaging system (Dazzle DVC100 Video). Data analyses were performed using active-monitoring software (smart3.0).
The one-trial Novel Object Recognition (NOR) test was carried out using an open-field apparatus (40 × 40 × 40 cm; Panlad, Spain) as the test box. The protocol consisted of two test sessions separated by a delay of over 20 min, during which the mice were returned to their home cage. In each test session, every mouse was placed in the same area, and then left to explore the open field for 5 min. In the first session, the mice were trained in the arena where two cubes (5 × 5 × 5 cm, familiar object) were placed as objects A and B. In the second session, the mice were trained in the arena where one object A and one cylinder (5 cm diameter, 5 cm height, novel object), designated as object C, were placed. The time and distance of novel and familiar objects exploration were recorded with a video-imaging system (Dazzle DVC100 Video) during each session. Data analyses were performed using active-monitoring software (smart3.0). The ratio of object C exploration time to total time represents the object recognition index.
Plasmids constructs
Request a detailed protocolFull-length cDNAs encoding human ACOTs (gene ID: 25082 for ACOT1, gene ID: 15824 for ACOT2, gene ID: 9637 for ACOT4, gene ID: 24012 for ACOT8, gene ID: 17595 for ACOT9, gene ID: 10617 for ACOT11, and gene ID: 134526 for ACOT12) were obtained from the Core Facility of Biomedical Sciences, Xiamen University. Point mutations of ACOT12 (ACOT12 R312E and R313E) (Lu et al., 2019) and ACOT8 (ACOT8 H78A) (Ishizuka et al., 2004) were constructed by PCR-mediated mutagenesis using PrimerSTAR DNA polymerase (Takara). cDNAs for proteins expression were constructed in pLV cs2.0 vectors. shRNAs were constructed in lentivirus-based pLL3.7 vectors. shRNAs against mouse Acot12 (#5, #6, and #7) and mouse Acot8 (#1 and #2) were also constructed in pAdEasy-1 (Stratagene) for adenovirus packaging based on The AdEasy Technology (He et al., 1998).
Cell culture, transfections, and cell treatments
Request a detailed protocolHeLa, HEK-293T, HT1080, Huh7, LO2, H3255, A549, QBI-293A, and HEB cell lines were taken from our laboratory cell bank and authenticated by Short Tandem Repeat (STR) profiling analysis. HCT116, 786-O, HepG2, Hepa1-6, and AML12 cell lines were obtained from and authenticated by the Cell Bank of the Chinese Academy of Sciences (Shanghai). All cells tested negative for mycoplasma infection using a PCR-based Mycoplasma Detection Kit (Sigma, MP0035-1KT).
Mouse embryonic fibroblast cells were isolated from the embryos of mice at 13.5 days post-coitum and further immortalized by infection with the SV-40 larger T antigen expressing retroviruses. All of the cell lines were cultured in DMEM (Gibco) with 10% fetal bovine serum (FBS, Gemini) at 37°C in an incubator containing 5% CO2. HEK-293T was used for transient transfection and lentivirus package with polyethylenimine (10 μM, Polyscience) as a transfection reagent. The virus-containing medium was collected after 24 hr of transfection, filtered with a 0.45-μm Steriflip filter (Millipore) and stored at −80°C for infection. The infected cells were passaged until stable cell lines were constructed. For all kinds of treatment, cells were seeded in 35 mm dishes and cultured for 24 hr before treatment. To measure glucose-derived acetate, cells were rinsed with phosphate-buffered saline (PBS) and then incubated in glucose-free DMEM (1 ml, Gibco) supplemented with 10% FBS and 10 mM U-13C-glucose for 20 hr before harvest. To measure fatty-acid-derived acetate, cells were rinsed with PBS and then incubated in HBSS supplemented with 10% FBS and 500 μM bovine serum albumin (BSA, fatty acids free, Yeasen Biotech)-conjugated FFA (myristate, palmitate, stearate, or U-13C-palmitate) for 20 hr before harvest. To determine amino-acid-derived acetate, cells were rinsed with PBS and then incubated in HBSS supplemented with 10% FBS and 2× or 4× amino acids for 20 hr before harvest. 2× amino acids contains double concentrations of amino acids in DMEM and 4× contains quadruple concentrations of amino acids in DMEM. HBSS media (1 l, pH 7.4) contains CaCl2 (140 mg), MgCl2·6H2O (100 mg), MgSO4·7H2O (100 mg), KCl (400 mg), KH2PO4 (60 mg), NaHCO3 (350 mg), NaCl (8 g), and Na2HPO4 (48 mg). To determine gluconeogenesis, cells were rinsed with PBS and then incubated in HBSS media (glucose-free) supplemented with 100 nM glucagon (Acmec, G78830) for 4 hr before harvest as previously described (Liu et al., 2017).
Adenovirus packaging and infection
Request a detailed protocolSterile linearized recombinant AdEasy plasmids were transfected into QBI-293A cell lines with Turbofect transfection reagent for adenovirus packaging as described previously (He et al., 1998). Fresh QBI-293A cells were further infected by the primary adenoviruses for amplification and purification of recombinant adenovirus. The purified adenovirus was used for infection of MPHs in vitro and liver cells in vivo.
Isolation of mouse primary hepatocytes
Request a detailed protocolMPHs were obtained from C57BL/6 mice by perfusing the liver through the portal vein with calcium-free buffer A (1 mM EGTA (ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid) and Kreb-Ringer buffer), followed by perfusion with buffer B (collagenase-IV from Sigma, Kreb-Ringer buffer and 5 mM CaCl2). Hepatic parenchymal cells were maintained in DMEM containing 10% FBS and precipitated by centrifugation (50 g for 3 min). Next, the isolated cells were plated in dishes that were pre-treated with collagen-I (CORNING) and cultured in DMEM with 10% FBS at 37°C in a humid incubator containing 5% CO2. Kreb-Ringer buffer (1 l, pH 7.4) contains NaCl (7 g), NaHCO3 (3 g), HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 5 mM, pH 7.45), Solution C (10 ml), and glucose (1 g). Solution C contains KCl (480 mM), MgSO4 (120 mM), and KH2PO4 (120 mM). All of the buffers and media described above contained penicillin (100 IU, Sangon Biotech) and streptomycin (100 mg/ml, Sangon Biotech) (Huang et al., 2011).
Immunoprecipitation and western blot
Request a detailed protocolCells or tissues were harvested in a lysis buffer (20 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA (ethylenediaminetetraacetic acid), 2.5 mM sodium pyrophosphate, 1 mM β-glycerolphosphate, 1 mM sodium orthovanadate, 1 mM EGTA, 1% Triton, 1 μg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride), sonicated and centrifuged at 20,000 × g for 15 min at 4°C. For immunoprecipitation, the supernatant was incubated with the corresponding antibody for 12 hr at 4°C and then incubated with A/G plus-agarose beads (Santa Cruz Biotechnology, Inc) for 2 hr at 4°C. For western blot, immunoprecipitates or total cell lysate supernatant was added to sodium dodecyl sulfate (SDS) loading buffer, boiled for 10 min and separated by SDS–polyacrylamide gel electrophoresis, followed by transfer to PVDF (polyvinylidene fluoride) membranes (Roche). The PVDF membranes were incubated with specific antibodies for 3 hr and the proteins were visualized using an enhanced chemiluminescence system. The intensity of the blots was analyzed using ImageJ.
Subcellular fraction purification
Request a detailed protocolFor subcellular fraction purification, the Peroxisome Isolation kit (Sigma) was used to isolate peroxisomes from primary hepatocytes by referring to the protocol provided by Sigma-Aldrich. The isolated subcellular fractions were lysed with lysis buffer and analyzed by western blot.
Immunofluorescence
Request a detailed protocolLO2 cells grown on coverslips at 30%–40% of confluence were washed with PBS and fixed in 4% paraformaldehyde for 10 min. The fixed cells were treated with 0.2% Triton X-100 in PBS for 10 min at room temperature to permeabilize the membrane and then incubated with 5% BSA in TBST (20 mM Tris, 150 mM NaCl, and 0.1% Tween 20) for 1 hr to block non-specific binding sites. Next, the cells were incubated with primary antibodies diluted in TBST containing 5% BSA for 1 hr at room temperature and washed three times with 0.02% Triton X-100 in PBS, followed by incubation with fluorescent secondary antibodies for 1 h. After washing three times with 0.02% Triton X-100 in PBS, all coverslips were counterstained with DAPI (4′,6-diamidino-2-phenylindole) and mounted on microscope slides with 90% glycerol. Images were captured using a Leica TCS SP8 confocal microscope at pixels of 1024 × 1024.
Biochemical analyses
Request a detailed protocolTo prepare mouse serum, mouse blood was collected into 1.5 ml Eppendorf tubes and allowed to clot for 30 min at 4°C. Then, samples were centrifuged for 30 min (1300 × g) at 4°C and the serum layer was carefully moved into a new 1.5 ml Eppendorf tube. Plasma levels of TG, CHOL, HDL-C, and LDL-C were measured in the Clinical Laboratory of Zhongshan Hospital, which is affiliated to Xiamen University. Plasma insulin levels were measured using the MOUSE INS-1055 ELISA KIT (Meikebio) with a standard curve, following the manufacturer’s protocol. Plasma total FFAs levels were measured using the FFA content assay kit (Beijing Boxbio Science & Technology) with a standard curve, following the manufacturer’s protocol, and each FFA was measured by gas chromatography — mass spectrometry (GC–MS). Fasted mice were fasted for 12 hr; non-fasted mice were fed normally.
Gas chromatography–mass spectrometry
Request a detailed protocolTo identify the acetate produced by cells, metabolites in the culture medium were subjected to acidification and extraction, followed by analysis using GC–MS as previously described but with some optimization (Fellows et al., 2018). First, equal amounts of propionic acid and butyric acid were added to cell-cultured media (100 μl) in Eppendorf tubes as an internal reference. Subsequently, 40 mg of sodium chloride, 20 mg of citric acid and 40 μl of 1 M hydrochloric acid were added to acidize the metabolites. After acidification, acetate, propionic acid, and butyric acid were liable to be extracted by 200 μl of n-butanol. Next, the tubes were vortexed for 3 min and centrifuged at 20,000 × g for 20 min. The supernatant was transferred to a high-performance liquid chromatography (HPLC) vial and 1 μl mixture was used for GC-MS.
For measurement of FFA levels, mouse serum was extracted as mentioned above and subjected to GC-MS. In brief, 30 μl of cold mouse serum was transferred to new 1.5 ml Eppendorf tubes and 500 μl of cold 50% methanol (containing 2.5 μg/ml tridecanoic acid as internal reference) was added to the samples, followed by the addition of 500 μl of cold chloroform. Next, samples were vortexed at 4°C for 10 min and centrifuged (12,000 × g) at 4°C for 20 min to separate the phase. The chloroform phase containing the total fatty acid content was separated and lyophilized by nitrogen. Dried fatty acid samples were esterified with 100 μl 1% sulfuric acid in methanol for 60 min at 80°C and extracted by the addition of 100 μl n-hexane. The supernatant was transferred to a HPLC vial and 1 μl mixture was used for GC-MS.
Analysis was performed using an Agilent 7890B gas chromatography system. This system was coupled to an Agilent 5977B mass spectrometric detector and a fused-silica capillary DB-FFAP, with dimensions of 30 m × 0.25 mm internal diameter (i.d.), coated with a 0.25-µm thick layer. The initial oven temperature was 50°C, which was ramped to 110°C at a rate of 15°C min−1, to 180°C at a rate of 5°C min−1, to 240°C at a rate of 15°C min−1, and finally held at 240°C for 10 min. Helium was used as a carrier gas at a constant flow rate of 1 ml min−1 through the column. The temperatures and the mass spectral data were collected in a full scan mode (m/z 30–300).
Liquid chromatography–mass spectrometry
Request a detailed protocolThe metabolites of TCA cycle were determined by LC–MS as described (Hui et al., 2020). To prepare the samples for the measurement of metabolites in tissues, the equivalent tissues of brain or muscle were quenched by a pre-cold methanol solution (methanol:ddH2O = 4:1) and homogenized, followed by centrifugation (12,000 × g, 20 min). The supernatants were collected in new Eppendorf tubes and dried at 4°C before the pellets were resuspended in acetonitrile solution (acetonitrile:ddH2O=1:1) and transferred to a HPLC vial. To prepare the samples for the measurement of the intracellular metabolites of in vitro cultured cells, the medium was discarded and cells cultured in a 35 mm dish were gently washed twice with cold PBS, followed by the addition of pre-cold methanol solution (methanol:ddH2O = 4:1, containing 160 ng/ml U-13C-glutamine as internal reference) to each well. Samples were then handled as described above for the measurement of tissue metabolites. For the analysis of metabolites the samples prepared as described above, liquid chromatography was performed using a SCIEX ExionLC AD system, with all chromatographic separations using a Millipore ZIC-pHILIC column (5 μm, 2.1 × 100 mm internal dimensions, PN: 1.50462.0001). The column was maintained at 40°C and the injection volume of all samples was 2 μl. The mobile phase, which consisted of 15 mM ammonium acetate and 3 ml/l ammonium hydroxide (>28%) in LC–MS grade water (mobile phase A) and LC−MS grade 90% (vol/vol) acetonitrile in HPLC water (mobile phase B), ran at a flow rate of 0.2 ml/min. The ingredients were separated with the following gradient program: 95% B for 2 min, then changed to 45% B within 13 min (linear gradient) and maintained for 3 min, then changed to 95% B directly and maintained for 4 min. The flow rate was 0.2 ml/min. The QTRAP mass spectrometer used an Turbo V ion source, which was run in negative mode with a spray voltage of −4500 V, with Gas1 40 psi, Gas2 50 psi, and Curtain gas 35 psi. Metabolites were measured using the multiple reactions monitoring mode. The relative amounts of metabolites were analyzed using MultiQuant Software Software (AB SCIEX).
NMR measurements
Request a detailed protocolTo prepare the culture medium samples for NMR analysis, medium harvested after the treatment of cells were centrifuged (12,000 × g at 4°C for 10 min) and the supernatants (400 μl) were transferred into 5 mm NMR tubes for NMR measurement. The clinical serum samples (200 μl) were thawed on ice, mixed with 200 μl NMR buffer (50 mM sodium phosphate buffer, pH 7.4 in D2O) and centrifuged (12,000 × g) at 4°C for 10 min. The supernatants (400 μl) were transferred into 5 mm NMR tubes for NMR measurement. For preparation of mouse blood samples, 25 μl blood was mixed with 75 μl saline immediately, and centrifuged (3000 × g) at 4°C for 10 min. The supernatants (100 μl) were mixed with 300 μl NMR buffer and transferred into 5 mm NMR tubes for NMR measurement. An internal tube containing 200 μl D2O (used for field-frequency lock) with 1 mM sodium 3-(trimethylsilyl) propionate-2,2,3,3-d4 (TSP) was used to provide the chemical shift reference (δ 0.00) and to quantify the metabolites.
NMR measurements were performed on a Bruker Avance III 850 MHz spectrometer (Bruker BioSpin, Germany) equipped with a TCI cryoprobe at 25°C provided by the College of Chemistry and Chemical Engineering (Xiamen University) and a Bruker Avance III 600 MHz spectrometer (Bruker BioSpin, Germany) provided by the Core Facility of Biomedical Sciences (Xiamen University). One-dimensional (1D) CPMG spectra were acquired using the pulse sequence [RD-90°-(τ-180°-τ)n-ACQ] with water suppression for culture medium and serum samples. For the purpose of metabolite resonance assignments, two-dimensional (2D) 1H-13C heteronuclear single quantum coherence spectra were recorded on selected NMR samples. Identified metabolites were confirmed by a combination of 2D NMR data and the Human Metabolome Data Base (HMDB).
FAO measurement
Request a detailed protocolFAO measurement was carried out as previously described (Li et al., 2018). Briefly, cells were cultured in 35 mm dishes and rinsed twice with PBS to remove the residue medium. 1 ml reaction buffer (119 mM NaCl, 10 mM HEPES (pH 7.4), 5 mM KCl, 2.6 mM MgSO4, 25 mM NaHCO3, 2.6 mM KH2PO4, 2 mM CaCl2, 1 mM BSA-congregated oleic acid and 0.8 μCi/ml [9,10-3H(N)]-oleic acid) was added to each dish and cells were incubated at 37°C for 12 hr, followed by centrifugation (1000 × g, 5 min) to obtain a supernatant. Then, 192 μl of 1.3 M perchloric acid was added to 480 μl of supernatant. The mixture was centrifuged (20,000 × g, 5 min) and 240 μl of the resulting supernatant was mixed with 2.4 ml of scintillation liquid and 3H radioactivity, followed by measurement with a liquid scintillation counter (Tri-Carb 2008TR, Perkins Elmer, USA; provided by the Center of Major Equipment and Technology (COMET), State Key Laboratory of Marine Environmental Science, Xiamen University).
Database analysis
Request a detailed protocolThe RNA-Seq data were downloaded from the GSE72086 dataset (Goldstein et al., 2017) of the public NCBI Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/), analyzed using the limma package (Ritchie et al., 2015), and visualized using the ggplot2 and ggrepel packages in R (version 3.6.3). GSE72086 contains six samples: three fed treatments and three fasted 24 hr treatments. Here, the probe with the greatest p value was chosen to determine the differential gene expression for multiple probes corresponding to the same gene. Adjusted p value <0.05 and |log fold change (log FC) | ≥ 1 were chosen as the threshold values.
The tissue-specific mRNA expression of the target gene was analyzed using the GTEx database (https://www.gtexportal.org/home/) for the human data and GSE24207 of the GEO database for the mice data, as reported previously (Fagerberg et al., 2014; Thorrez et al., 2011).
Statistical analysis
Request a detailed protocolThe two-tailed Student’s t-test was performed, using GraphPad Prism 8 and Excel, to analyze the difference between two groups. One-way analysis of variance was performed using GraphPad Prism 9 and R (version 3.6.3) to compare values among more than two groups. Difference was considered significant if the p value was lower than 0.05 (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
Appendix 1
Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
---|---|---|---|---|
Gene (Homo-sapiens) | ACOT1 | Core Facility of Biomedical Sciences, Xiamen University | Gene ID: 25082 | |
Gene (Homo-sapiens) | ACOT2 | Core Facility of Biomedical Sciences, Xiamen University | Gene ID: 15824 | |
Gene (Homo-sapiens) | ACOT4 | Core Facility of Biomedical Sciences, Xiamen University | Gene ID: 9637 | |
Gene (Homo-sapiens) | ACOT8 | Core Facility of Biomedical Sciences, Xiamen University | Gene ID: 24012 | |
Gene (Homo-sapiens) | ACOT9 | Core Facility of Biomedical Sciences, Xiamen University | Gene ID: 17595 | |
Gene (Homo-sapiens) | ACOT11 | Core Facility of Biomedical Sciences, Xiamen University | Gene ID: 10617 | |
Gene (Homo-sapiens) | ACOT12 | Core Facility of Biomedical Sciences, Xiamen University | Gene ID: 134526 | |
Cell line (Homo-sapiens) | HeLa | Our laboratory cells bank | Cell line maintained in our laboratory cells bank | |
Cell line (Homo-sapiens) | HEK-293T | Our laboratory cells bank | Cell line maintained in our laboratory cells bank | |
Cell line (Homo-sapiens) | HT1080 | Our laboratory cells bank | Cell line maintained in our laboratory cells bank | |
Cell line (Homo-sapiens) | Huh7 | Our laboratory cells bank | Cell line maintained in our laboratory cells bank | |
Cell line (Homo-sapiens) | LO2 | Our laboratory cells bank | Cell line maintained in our laboratory cells bank | |
Cell line (Homo-sapiens) | H3255 | Our laboratory cells bank | Cell line maintained in our laboratory cells bank | |
Cell line (Homo-sapiens) | A549 | Our laboratory cells bank | Cell line maintained in our laboratory cells bank | |
Cell line (Homo-sapiens) | QBI-293A | Our laboratory cells bank | Cell line maintained in our laboratory cells bank | |
Cell line (Homo-sapiens) | HEB | Our laboratory cells bank | Cell line maintained in our laboratory cells bank | |
Cell line (Homo-sapiens) | HCT116 | Cell Bank of the Chinese Academy of Sciences (Shanghai) | Cell line maintained in Cell Bank of the Chinese Academy of Sciences (Shanghai) | |
Cell line (Homo-sapiens) | 786-O | Cell Bank of the Chinese Academy of Sciences (Shanghai) | Cell line maintained in Cell Bank of the Chinese Academy of Sciences (Shanghai) | |
Cell line (Homo-sapiens) | HepG2 | Cell Bank of the Chinese Academy of Sciences (Shanghai) | Cell line maintained in Cell Bank of the Chinese Academy of Sciences (Shanghai) | |
Cell line (mouse) | Hepa1-6 | Cell Bank of the Chinese Academy of Sciences (Shanghai) | Cell line maintained in Cell Bank of the Chinese Academy of Sciences (Shanghai) | |
Cell line (mouse) | AML12 | Cell Bank of the Chinese Academy of Sciences (Shanghai) | Cell line maintained in Cell Bank of the Chinese Academy of Sciences (Shanghai) | |
Transfected construct (human) | ACLY shRNA-#1 | This paper | Lentiviral construct to transfect and express the shRNA; Targeting sequence: GCAGCAGACCTATGACTATGC | |
Transfected construct (human) | ACLY shRNA-#2 | This paper | Lentiviral construct to transfect and express the shRNA; Targeting sequence: GCATCGCAAACTTCACCAACG | |
Transfected construct (human) | ACLY shRNA-#3 | This paper | Lentiviral construct to transfect and express the shRNA; Targeting sequence: GCACGAAGTCACAATCTTTGT | |
Transfected construct (human) | ACLY shRNA-#4 | This paper | Lentiviral construct to transfect and express the shRNA; Targeting sequence: GCAAGGCATGCTGGACTTTGA | |
Transfected construct (human) | CPT1A shRNA-#3 | This paper | Lentiviral construct to transfect and express the shRNA; Targeting sequence: TACAGTCGGTGAGGCCTCTTATGAA | |
Transfected construct (human) | CPT1A shRNA-#4 | This paper | Lentiviral construct to transfect and express the shRNA; Targeting sequence: GGACCAAGATTACAGTGGTATTTGA | |
Transfected construct (human) | ABCD1 shRNA-#1 | This paper | Lentiviral construct to transfect and express the shRNA; Targeting sequence: GCAGATCAACCTCATCCTTCT | |
Transfected construct (human) | ACOT12 shRNA-#1 | This paper | Lentiviral construct to transfect and express the shRNA; Targeting sequence: GCTAGAGTTGGACAAGTTATA | |
Transfected construct (human) | ACOT12 shRNA-#2 | This paper | Lentiviral construct to transfect and express the shRNA; Targeting sequence: CAAATACCAGTGATTTGGATTAGCA | |
Transfected construct (mouse) | Acot12 shRNA-#5 | This paper | Lentiviral construct to transfect and express the shRNA; Targeting sequence: GCATGGAGATCAGTATCAAGG | |
Transfected construct (mouse) | Acot12 shRNA-#6 | This paper | Lentiviral construct to transfect and express the shRNA; Targeting sequence: GCAGGTTCAGCGATTCCATTT | |
Transfected construct (mouse) | Acot12 shRNA-#7 | This paper | Lentiviral construct to transfect and express the shRNA; Targeting sequence: GCGAGGACGATCAGATATATT | |
Transfected construct (human) | ACOT8 shRNA-#1 | This paper | Lentiviral construct to transfect and express the shRNA; Targeting sequence: GAGGATCTCTTCAGAGGAAGG | |
Transfected construct (human) | ACOT8 shRNA-#2 | This paper | Lentiviral construct to transfect and express the shRNA; Targeting sequence: GCAGCCAAGTCTGTGAGTGAA | |
Transfected construct (mouse) | Acot8 shRNA-#1 | This paper | Lentiviral construct to transfect and express the shRNA; Targeting sequence: GGGACCCTAACCTTCACAAGA | |
Transfected construct (mouse) | Acot8 shRNA-#2 | This paper | Lentiviral construct to transfect and express the shRNA; Targeting sequence: GCTGTGTGGCTGCTTATATCT | |
Antibody | anti-Flag (mouse monoclonal) | Sigma | Cat#F1804 RRID:AB_262044 | IF (1:200) WB (1:2000) |
Antibody | anti-ACOT12 (rabbit polyclonal) | Abbkine | Cat#ABP53776 | WB (1:500) |
Antibody | anti-ACOT8 (rabbit polyclonal) | Abbkine | Cat#ABP50586 | WB (1:500) |
Antibody | anti-HMGCS2 (rabbit polyclonal) | ABclonal | Cat#A14244 RRID:AB_2761104 | WB (1:1000) |
Antibody | anti-ABCD1 (rabbit polyclonal) | Abbkine | Cat#ABP54187 | WB (1:1000) |
Antibody | anti-β-actin (mouse monoclonal) | Proteintech | Cat#60008-1-Ig RRID:AB_2289225 | WB (1:2000) |
Antibody | anti-ACLY (rabbit polyclonal) | Proteintech | Cat#15421-1-AP RRID:AB_2223741 | WB (1:500) |
Antibody | anti-CPT1A (rabbit polyclonal) | Proteintech | Cat#15184-1-AP RRID:AB_2084676 | WB (1:500) |
Antibody | anti-catalase (mouse monoclonal) | Proteintech | Cat#66765-1-Ig RRID:AB_2882111 | IF (1:100) |
Antibody | anti-TOMM40 (mouse monoclonal) | Proteintech | Cat#66658-1-Ig RRID:AB_2882015 | WB (1:2000) |
Antibody | anti-LAMP2 (mouse monoclonal) | Proteintech | Cat#66301-1-Ig RRID:AB_2881684 | WB (1:2000) |
Antibody | anti-GAPDH (rabbit monoclonal) | Proteintech | Cat#60004-1-Ig RRID:AB_2107436 | IF (1:100) WB (1:2000) |
Antibody | Acetylated-lysine antibody (rabbit polyclonal) | Cell Signaling Technology | Cat#9441S RRID:AB_331805 | WB (1:1000) |
Antibody | HRP-conjugated goat anti-mouse IgG antibody | Thermo Fisher | Cat#A16072SAM PLE | WB (1:5000) |
Antibody | HRP-conjugated goat anti-rabbit IgG antibody | Thermo Fisher | Cat#A16104SAM PLE | WB (1:5000) |
Commercial assay or kit | Peroxisome Isolation kit | Sigma | PEROX1-1KT | |
Commercial assay or kit | PCR-based Mycoplasma Detection Kit | Sigma | MP0035-1KT | |
Chemical compound, drug | Streptozotocin | Sangon Biotech | Cat#A610130-0100 | |
Chemical compound, drug | Ampicillin | Sangon Biotech | Cat#A610028-0025 | |
Chemical compound, drug | Streptomycin | Sangon Biotech | Cat#A610494-0250 | |
Chemical compound, drug | Tetradecanoic acid | Sangon Biotech | Cat#A600931-0250 | |
Chemical compound, drug | Sodium stearate | Sangon Biotech | Cat#A600888-0100 | |
Chemical compound, drug | Colistin | Yuanye Bio-Technology | Cat#1264-72-8 | |
Chemical compound, drug | Deuterated water (D2O) | Qingdao Tenglong Weibo Technology | Cat#DFSA180309 G100 | |
Chemical compound, drug | Sodium 3-(trimethylsilyl) propionate-2,2,3,3-d4 (TSP) | Qingdao Tenglong Weibo Technology | Cat#DLM-48–5 | |
Chemical compound, drug | Etomoxir | MedChemExpress (MCE) | Cat#828934-41-4 | |
Chemical compound, drug | Sodium palmitate | Sigma | Cat#P9767-10G | |
Chemical compound, drug | Sodium acetate | Sigma | Cat#791741-100G | |
Chemical compound, drug | Sodium 3-hydroxybutyrate | Sigma | Cat#54965-10G-F | |
Chemical compound, drug | U-13C-palmitate | Cambridge Isotope Laboratories | Cat#CLM-6059–1 | |
Chemical compound, drug | U-13C-glucose | Cambridge Isotope Laboratories | Cat#CLM-1396-1 | |
Chemical compound, drug | U-13C-glutamine | Cambridge Isotope Laboratories | Cat#CLM-1822-H-0.1 | |
Chemical compound, drug | U-13C-acetate | Cambridge Isotope Laboratories | Cat#CLM-440-1 | |
Chemical compound, drug | 2-13C-acetate | Cambridge Isotope Laboratories | Cat#CLM-381-5 | |
Chemical compound, drug | DAPI stain | Sigma | D9542 | |
Software, algorithm | R | R-studio | R (version 3.6.3) |
Data availability
All data generated or analyzed during this study are included in the manuscript and supporting file. Source data files have been provided for Figures 1, 3, 4, 5, and 7. The numerical data utilized for the generation of the figures has been duly submitted to the Mendeley Data repository (https://doi.org/10.17632/xvs8292ytz.1).
-
Mendeley DataHepatic conversion of acetyl-CoA to acetate plays crucial roles in energy stresses.https://doi.org/10.17632/xvs8292ytz.1
-
NCBI Gene Expression OmnibusID GSE24207. mRNA analysis in different mouse tissues.
-
NCBI Gene Expression OmnibusID GSE72086. Characterization of chromatin and gene expression changes during fasting in mouse liver [RNA-Seq].
References
-
The relationship of plasma acetate with glucose and other blood intermediary metabolites in non-diabetic and diabetic subjectsClinica Chimica Acta; International Journal of Clinical Chemistry 185:25–34.https://doi.org/10.1016/0009-8981(89)90127-7
-
Fuel metabolism in starvationAnnual Review of Nutrition 26:1–22.https://doi.org/10.1146/annurev.nutr.26.061505.111258
-
A metabolic switch in brain: glucose and lactate metabolism modulation by ascorbic acidJournal of Neurochemistry 110:423–440.https://doi.org/10.1111/j.1471-4159.2009.06151.x
-
The redox switch/redox coupling hypothesisNeurochemistry International 48:523–530.https://doi.org/10.1016/j.neuint.2005.12.036
-
Carbohydrate responsive element binding protein and lipid homeostasisCurrent Opinion in Lipidology 19:301–306.https://doi.org/10.1097/MOL.0b013e3282ffafaa
-
Hepatic gene regulation by glucose and polyunsaturated fatty acids: a role for ChREBPThe Journal of Nutrition 136:1145–1149.https://doi.org/10.1093/jn/136.5.1145
-
Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomicsMolecular & Cellular Proteomics 13:397–406.https://doi.org/10.1074/mcp.M113.035600
-
Impact of overweight on the risk of developing common chronic diseases during a 10-year periodArchives of Internal Medicine 161:1581–1586.https://doi.org/10.1001/archinte.161.13.1581
-
The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulationAmerican Journal of Physiology. Endocrinology and Metabolism 280:E827–E847.https://doi.org/10.1152/ajpendo.2001.280.6.E827
-
Energy metabolism, fuel selection and body weight regulationInternational Journal of Obesity 32:S109–S119.https://doi.org/10.1038/ijo.2008.246
-
Quantitative fluxomics of circulating metabolitesCell Metabolism 32:676–688.https://doi.org/10.1016/j.cmet.2020.07.013
-
Overexpression of human acyl-CoA thioesterase upregulates peroxisome biogenesisExperimental Cell Research 297:127–141.https://doi.org/10.1016/j.yexcr.2004.02.029
-
Getting a handle on the role of coenzyme M in alkene metabolismMicrobiology and Molecular Biology Reviews 72:445–456.https://doi.org/10.1128/MMBR.00005-08
-
Rat liver peroxisomes catalyze the beta oxidation of fatty acidsThe Journal of Biological Chemistry 253:1522–1528.
-
Free acetate production by rat hepatocytes during peroxisomal fatty acid and dicarboxylic acid oxidationThe Journal of Biological Chemistry 264:10347–10350.
-
The oxidation of glucose, ketone bodies and acetate by the brain of normal and ketonaemic sheepThe Journal of Physiology 259:801–823.https://doi.org/10.1113/jphysiol.1976.sp011496
-
Real-time imaging of the pancreas during development of diabetesImmunological Reviews 221:200–213.https://doi.org/10.1111/j.1600-065X.2008.00581.x
-
Balancing mitochondrial biogenesis and mitophagy to maintain energy metabolism homeostasisCell Death and Differentiation 22:1399–1401.https://doi.org/10.1038/cdd.2015.86
-
Physiological roles of ketone bodies as substrates and signals in mammalian tissuesPhysiological Reviews 60:143–187.https://doi.org/10.1152/physrev.1980.60.1.143
-
Energetics of bacterial growth: balance of anabolic and catabolic reactionsMicrobiological Reviews 59:48–62.https://doi.org/10.1128/mr.59.1.48-62.1995
-
The metabolic fate of acetate in cancerNature Reviews. Cancer 16:708–717.https://doi.org/10.1038/nrc.2016.87
-
Effect of long-term starvation on acetate and ketone body metabolism in obese patientsEuropean Journal of Clinical Investigation 14:163–170.https://doi.org/10.1111/j.1365-2362.1984.tb02107.x
-
Spatiotemporal Control of Acetyl-CoA Metabolism in Chromatin RegulationTrends in Biochemical Sciences 43:61–74.https://doi.org/10.1016/j.tibs.2017.11.004
-
Deactivating Fatty Acids: Acyl-CoA Thioesterase-Mediated Control of Lipid MetabolismTrends in Endocrinology and Metabolism 28:473–484.https://doi.org/10.1016/j.tem.2017.03.001
-
Plasma acetate levels in a group of obese diabetic, obese normoglycemic, and control subjects and their relationships with other blood parametersThe American Journal of Gastroenterology 88:751–755.
Peer review
Reviewer #1 (Public Review):
The authors investigate the roles of ACOT12/8 in the production of acetate by the liver. They observe that acetate concentration parallels ketone concentrations during fasting and T1DM. They show that acetate is produced from fatty acids in hepatocytes, but though described as a novel "ketone body", this acetate is not a product of ketogenesis or acetoacetate. They also provide serum acetate data from human subjects who were classified as either "healthy" or "diabetic,". These subjects are noted as T2DM patients, but there is no other characterization or description, making it difficult to ascertain the context in which they were studied or their relevance to the mouse studies. Although the function of ACOT12/8 is reported in the literature, they are not widely studied, and there also remains surprising uncertainties regarding the mechanism of acetate production by the liver. In this regard, the manuscript provides some important insight. The authors use ShACOT12/8 and ACOT12/8 knockout mice to demonstrate that these acetyl-CoA hydrolases are largely necessary for acetate production. Using a 3H-palmitate assay, the authors then find that loss of these ACOTs inhibit fatty acid oxidation and propose that the mechanism involves scavenging CoA, analogous to the canonical role of ketogenesis. The idea is plausible but not proven. A related finding is that loss of these ACOTs inhibit ketogenesis, which the authors attribute to the loss of function of HMGC2S, partially through acetylation. These mechanisms suffer some limitations based on the cytosolic and mitochondrial compartmentation of the two processes, but the observations appear sound. Interestingly, the loss of the ACOTs have a more profound effect on lowering ketones than acetate, which may have parallel effects but they are not investigated. Finally, the authors try to demonstrate that hepatic ACOT-mediated acetate production is necessary for normal motor function in STZ treated mice, ostensibly as compensation for impaired glucose utilization by the CNS. Injections of 13C acetate and 13C enrichment in downstream metabolites of brain are used to support the importance of acetate metabolism, but the experiment was not performed in loss of function models. In addition, the resulting 13C enrichment data is reported generically as "relative intensity" without further elaboration on how this data was generated and should not be taken at face value by the reader. Conceptually, one may also be skeptical of the rather dramatic loss of motor function in the context of a relatively minor circulating nutrient. Nevertheless, this finding may be important if more supporting evidence with proper controls for ketone concentrations can be provided. Overall, there are important data in the manuscript, but the reader may find it difficult to navigate the 20+ figure panels. The most important findings are that ACOT12/8 are critical for hepatic acetate production in mice, which will be helpful for the field, but the ramifications require more rigorous investigation.
https://doi.org/10.7554/eLife.87419.3.sa1Reviewer #2 (Public Review):
Catabolic conditions lead to increased formation of ketone bodies in the liver, which under these conditions play an important role in supplying energy to metabolically active organs. In this manuscript, the authors explore the concept of whether and to what extent hepatic formation of acetate might contribute to energy supply under metabolic stress conditions. The authors show that patients with diabetes have increased acetate levels, which is explained as a consequence of the increased fatty acid flux from adipose tissue to the liver. This is confirmed in a preclinical model for type 1 diabetes, where acetate concentrations are in a similar range to ketone bodies. Acetate concentrations also increase under physiological conditions of fasting. Using stable isotopes, the authors show that palmitate is used as the primary source for acetate production in primary hepatocytes. Using cell culture studies and adenoviral-mediated knockdown in mice, it can be shown that the conversion of acetyl-CoA to acetate is catalyzed in peroxisomes by acyl-CoA thioesterase8 (ACOT8) and after transport of citrate from mitochondria and subsequent conversion to acetyl-CoA in the cytosol by ACOT12. Remarkably, ACOT8/12 not only regulates the formation of acetate but plays a crucial role in the maintenance of cellular CoA concentration. Accordingly, depletion of ACOT8/12 activity leads to a reduction of other CoA derivatives such as HMG-CoA, which resulted in the inhibition of ketone body synthesis. In diabetic mice, ACOT 8 or ACOT12 knockdown appears to lead to some limitations in strength and behavior.
In summary, the authors clearly demonstrate that hepatic release-mediated by ACOT8 and ACOT12-determines the plasma concentration of acetate. This is a very remarkable observation since most studies assume that short-chain fatty acids in plasma are primarily generated by fermentation of dietary fiber by intestinal bacteria. The authors demonstrate in very well performed studies the metabolic changes that result from impaired thiolysis. On the other hand, the ACOT12 phenotype has been demonstrated in a recently published study (PMID: 34285335). In this study, ACOT12 deficiency caused NAFLD, thus it would be worth determining whether deficiency of ACOT12 and/or ACOT8 promotes de novo lipogenesis under the conditions of the present study. As a further limitation, it should be noted that the relevance of acetate production for the energy supply of peripheral organs including the central nervous system could not be clearly demonstrated. For instance, impaired ketone body production due to impaired CoA availability could affect the metabolic activity of various organs. Moreover, the human cohort is not very well described, e.g. it is unclear whether the patients have type 1 or type 2 diabetes.
https://doi.org/10.7554/eLife.87419.3.sa2Reviewer #3 (Public Review):
Wang et al. investigated the role of acetate production, a byproduct of fatty acid oxidation, in the context of metabolic stressors, including diabetes mellitus and prolonged fasting. Mechanistically, they show the importance of the liver enzymes ACOT8 (peroxisome) and ACOT12 (cytoplasm) in converting FFA-derived acetyl-CoA into acetate and CoA. The regeneration of CoA allows for subsequent fatty acid oxidation. Inhibiting the generation of acetate has negative motor consequences in streptozocin-treated mice, which are mitigated with acetate injection.
This paper's strengths include using multiple mouse models, metabolic stressors (db/db-/-, streptozocin, and prolonged starvation), numerous cell lines, precise knockout and rescue experiments, and complimentary use of mass spectrometry and nuclear magnetic resonance analytical platforms. The presented data support the conclusions of this paper and highlight the role of acetate in energy stress conditions.
In clinical medicine, common ketones that are measured are acetoacetate, beta-hydroxybutyrate, and acetone which can help determine the severity of illness. However, the data presented here suggest the potential importance of measuring acetate as another biomarker when patients present with ketoacidosis in uncontrolled diabetes or starvation. This requires further investigation.
https://doi.org/10.7554/eLife.87419.3.sa3Author response
The following is the authors’ response to the original reviews
Reviewer #1 (Recommendations for the authors):
Major Concerns:
1. There are numerous grammatical issues throughout the manuscript, and too much awkward jargon is used, such as "status of energy stresses", "ES-acetate". The characterization of acetate as an "energy stress" gives a negative connotation, which is unnecessary and confusing. Ketones are produced under the same circumstances but are a vital adaptive response, except for ketoacidosis. The terminology used throughout the manuscript is also vague, and some methodology is not adequately described in the Methods section. For example, the meaning of "preprandial" and "postprandial" is unclear, and there is no explanation of the related methodology.
Thank you for your comments. We have replaced "status of energy stresses" with "energy stresses", in our revised manuscript. We agree with you that acetate and Ketone Bodies are produced under the same circumstances and their production is a result of a vital adaptive response. It is well known that the production of large amount of acetate and Ketone Bodies is an important physiological adaption of body in response to energy stresses such as prolonged starvation and untreated diabetes mellitus. In this context, we use “energy stress-acetate”, a term coined by ourselves to emphasize the condition of acetate production and its role under such condition. Based on your concerns, we have addressed the issues and provided a thorough description of the modifications made in the Methods section.
1. The authors claim that acetate is a ketone body, which is incorrect. As the authors show, it is not produced by the ketogenic pathway or from the breakdown of ketones. Acetate is a carboxylic acid and specifically a short-chain fatty acid.
We agree with you that our description of acetate as a ketone body is seemingly incorrect. Indeed, acetate is a short-chain fatty acid in terms of molecular structure. The classic Ketone Bodies include acetone, acetoacetate and beta-hydroxybutyrate, among which acetone and acetoacetate contain carbonyl group and can be considered as ketone, however beta-hydroxybutyrate which contains only hydroxyl and carboxyl groups is actually not a ketone but a short-chain fatty acid.Noteworthily, here our description of acetate as an emerging novel “ketone body” is not aimed to consider it as a real ketone in structure, but to emphasize the high similarity of acetate and the classic Ketone Bodies in the organ (liver) and substrate (fatty acids-derived acetyl-CoA) of their production, the roles they played (as important sources of fuel and energy for many extrahepatic peripheral organs), the feature of their catabolism (converted back to acetyl-CoA and degraded in TCA cycle), as well as the physiological conditions of their production (energy stresses such as prolonged starvation and untreated diabetes mellitus). To prevent any potential misunderstanding, we annotate the usage of "ketone body" with double quotation marks in our revised manuscript.
1. The human subjects are not sufficiently characterized, and it is unclear whether they are T1DM or T2DM subjects. No information is provided on morphometrics, how and when serum was collected, exclusion criteria, medicines, etc. Proper characterization of human subjects is necessary before publishing such data.
Thank you very much for your comments. We have added the description of subjects you mentioned in the Methods section.
1. While Figure 4 is an essential set of experiments that demonstrate that ACOT12 is necessary for the induction of acetate during starvation in mice, the authors do not explain the source of basal levels of acetate that persist in mice lacking ACOT12. It is unclear whether this source is from other tissue or microbiota. Since loss of ACOT by ShRNA treatment resulted in ~25% reduction in acetate, it is very difficult to conceive how this produces the profound neurological and strength deficits presented in Supplemental Figure 8 (see last point below).
Additionally, it is not clear how the control mice for the knockout studies were generated. Please clarify.
In normal condition, the serum acetate level in mice is around 200 μM. Hepatic ACOT12 and ACOT8 enzymes seems to provide a serum acetate concentration of 60-90 μM, individually (Figure 4). The intestinal microbiota contributes a serum acetate concentration of 60-80 μM (Figure 2 and Figure supplement 1).
During energy stress, the protein levels of ACOT12 and ACOT8 in the mouse liver were significantly upregulated (Figure 3 and Figure supplement 1), resulting in an significant increase of serum acetate level to approximate 400 μM. The acetate produced by ACOT12 (~200 μM) and ACOT8 (~200 μM) constitutes the main portion of serum acetate concentration under such condition (Figure 2), while the contribution of intestinal microbiota to serum acetate level is minimized (Figure 2 and Figure supplement 1). Elimination of either ACOT12 or ACOT8 reduces serum acetate level by up to 50% (Figure 4). However, such estimation is only a rough approximation and does not consider the possibility of compensatory upregulation of ACOT12 and ACOT8 in kidney when ACOT12 or ACOT8 is knocked out in liver.
Acetate assumes the role as an important energy source in the case of reduced glucose utilization associated with diabetes. In this case, knockdown of ACOT12 or ACOT8 (shACOT12 or shACOT8) can remarkably reduce acetate production and consequently influence the Motor Function of mice to a certain extent.
1. The results presented in Figure 5 are confusing, and the authors' interpretation needs elaboration. The FAO assay detects water-soluble 3H-metabolites and 3H2O, and etimoxir or CPT1 knockout completely inhibits FAO. Therefore, it is unclear how peroxisomes can produce acetate without generating water-soluble intermediates that are detectable in the assay. Further explanation and rationale for the authors' interpretation are necessary.
Mitochondria serve as the primary organelle for the catabolism of oleic acid. However, in certain instances, fatty acid oxidation (FAO) can occur in the peroxisome, resulting in the production of medium-chain fatty acids and acetyl-CoA. Nevertheless, these medium-chain fatty acids cannot undergo further oxidation within the peroxisome. Instead, they must be transported out of the peroxisome and then into the mitochondria through CPT1 (carnitine palmitoyltransferase 1) for further oxidation.
To assess FAO, we utilized a detection method based on 3H labeling in H2O in cells treated with [9,10-3H(N)]-oleic acid. The introduction of [9,10-3H(N)]-oleic acid leads to the production of 3H-labeled medium-chain fatty acids and acetyl-CoA within the peroxisome. The further oxidation of 3H-labeled medium-chain fatty acids in the mitochondria was inhibited by impeding the activity of CPT1, leading to the eventual decrease of 3H-labeled H2O. However, acetyl-CoA can still be converted to acetate by ACOT8. As a result, knockdown or etomoxir inhibition of CPT1, decreased more than one-half of U-13C-palmitate-derived U-13C-acetate production, in spite of mitochondria β-oxidation being nearly completely abolished.
1. Figure 6F, which shows various fatty acyl-CoAs in MPHs, is not helpful on its own. It would be useful to compare this data to loss of function MPH data and to measure these acyl-CoAs in knockout liver. Additionally, since it is normal for liver acetyl-CoA concentration to change by several-fold in fasted and fed liver, this data from snap frozen liver tissue of ACOT12/8 KO mice would help prove the authors' point.
We are grateful for your valuable advice. As you mentioned there are indeed several outstanding questions that require further clarification. To address these questions, we are currently in the process of developing an experimental mouse model in which ACOT12 and ACOT8 are conditionally knocked out. By virtue of this approach, we aim to acquire more substantial evidence to substantiate the aforementioned conclusions.
1. Figure 7 suggests that loss of ACOT inhibits ketogenesis by decreasing HMGCS2 expression and increasing its acetylation. However, it is difficult to imagine that this the main mechanism considering the extraordinary ability of liver to handle high rates of acetyl-CoA conversion to ketones during fasting which, as the authors know, is the canonical mechanism by which mitochondrial CoA is preserved during elevated FAO. The manuscript (Figure 6 and 7) argues that it is the conversion of acetyl-CoA to acetate which is more important. A critical limitation of this argument is that ACOT12 is in cytosol (Figure 5), so while it spares CoA for fatty acid activation, it does not spare CoA for beta oxidation in mitochondria. That latter function is carried out by the ketogenic pathway. A second limitation is that the mechanism relies on citrate transport and ACLY activity, which is not generally thought to be very active in the ketogenic states of fasting and T1DM studied here. In essence, the mechanism relies on circular logic, whereby mitochondrial acetyl-CoA accumulates in the setting of impaired FAO, which then impairs ketogenesis and depletes CoA which then impairs FAO without lowering acetyl-CoA. I don't have a solution, but I think it is important to acknowledge the flaws in this proposed mechanism.
As the Reviewer suggested, ACLY indeed plays a crucial role in fatty acid synthesis. Acetyl-CoA is transported out of the mitochondria in the form of citrate, which is subsequently broken down into acetyl-CoA by ACLY. Under conditions of sufficient nutrition, acetyl-CoA carboxylase 1 further activates acetyl-CoA to participate in fatty acid synthesis.
In the context of an energy crisis resulting from low glucose utilization, we propose that ACLY might serve another pivotal role in addressing this energy deficit. In conditions such as untreated diabetes or prolonged starvation, glucose utilization is significantly reduced, leading to a reliance of body on fatty acid oxidation in liver to generate Ketone Bodies and acetate to fuels extrahepatic peripheral tissues and thus cope with the energy crisis. However, excessive fatty acid oxidation disrupts the balance between oxidized and reduced CoA, necessitating the production of both acetate and Ketone bodies to restore this equilibrium. Conventionally, fatty acid synthesis is inhibited during this period as AMPK is activated to suppress acetyl-CoA carboxylase 1 activity via phosphorylation in low-energy states. Based on our preliminary experimental results, the activity of ACLY and citrate transporter still appear to work well. It is possible that citrate-ACLY-ACOT12-acetate pathway is important for downregulating the level of mitochondria acetyl-CoA in energy crisis. According to previous studies, cytosolic reduced CoA has the capability to be transported into the mitochondria, thereby replenishing the acetyl-CoA pool within the mitochondria (PMID: 32234503). It is important to note that this remains a hypothesis requiring further testing.
1. Figure 8 presents some deceptively complex MS data following a 13C-acetate injection. The data is presented in an unorthodox manner, as 13C-metabolite intensities, making it nearly impossible to properly interpret. Enrichment of TCA cycle intermediates are not always easy to interpret, but at minimum, this data needs to be presented as MIDs or fractional enrichments. If the data is not modeled, then it might be useful to at least perform a rudimentary precursor-product analysis (i.e. normalized to plasma acetate enrichment).
Supplemental Figure 8 also introduces evidence for neurological and strength deficits in shACOT12/8 knockdown mice. It is an interesting observation, but there is no direct link to the metabolic studies in the main figure, which does not present data in the loss of function mice. Nor is this part of the story investigated in liver specific knockout mice. Figure 8 is the least developed part of the manuscript and could be removed without losing the impact of the story.
We deeply appreciate your valuable suggestions. As mentioned previously, we are currently engaged in the development of an experimental mouse model where ACOT12 and ACOT8 are selectively knocked out. Subsequent experiments will be conducted to validate this model, and the resulting data will be presented in the form of MIDs or fractional enrichments, as per your suggestion.
The evaluation of anxiety-related behavior is commonly done using the Elevated Plus Maze Test (EPMT), while working memory and cognitive functions are assessed through the Y-maze Test (YMZT) and Novel Object Recognition (NOR) Test. Measures such as forelimb strength and running time in the rotarod test, total distance in YMZT, total entries in YMZT, and total distance in the NOR test are indicators of muscle force and movement ability. Our data demonstrate that acetate plays a significant role in enhancing muscle force and facilitating coordinated neuromuscular movement. Interestingly, we found that ACOT12/8 knockdown in the early stages of diabetes mellitus does not have a pronounced impact on psychiatric, memory, and cognitive behaviors (Figure 8 and figure supplement 2). However, it is important to note that our study primarily focuses on elucidating the utilization of acetate during energy crises, such as untreated diabetes and chronic hunger. Our findings suggest that acetate is primarily utilized to enhance motor capacity rather than cognitive or neural activity.
Reviewer #2 (Recommendations for the authors):
The statement that acetate is an emerging ketone body is not correct. It is not a ketone, it is a carboxylic acid or a short-chain fatty acid. In my opinion, to avoid confusion this should be clarified.
We agree with you that our description of this is not clear enough. Acetate is a short-chain fatty acid in terms of molecular structure indeed.
The classic Ketone Bodies include acetone, acetoacetate and beta-hydroxybutyrate, among which acetone and acetoacetate contain carbonyl group and can be considered as ketone, however beta-hydroxybutyrate which contains only hydroxyl and carboxyl groups is actually not a ketone but a short-chain fatty acid.
Noteworthily, here our description of acetate as an emerging novel “ketone body” is not aimed to consider it as a real ketone in structure, but to emphasize the high similarity of acetate and the classic Ketone Bodies in the organ (liver) and substrate (fatty acids-derived acetyl-CoA) of their production, the roles they played (as important sources of fuel and energy for many extrahepatic peripheral organs), the feature of their catabolism (converted back to acetyl-CoA and degraded in TCA cycle), as well as the physiological conditions of their production (energy stresses such as prolonged starvation and untreated diabetes mellitus). To prevent any potential misunderstanding, we annotate the usage of "ketone body" with double quotation marks in our revised manuscript.
The reason for increased fatty acid delivery to the liver is explained by insulin resistance rather than by reduced carbohydrate availability.
Patient characteristics should be provided.
Thank you for your suggestions. We have revised our manuscript accordingly.
Reviewer #3 (Recommendations for the authors):
• Please include the rationale for having data from both C57BL/6 and BALC/c. In metabolic research, C57BL/6 is more commonly studied. The data between these two strains are similar, and one could be easily removed to limit redundancy.
Thank you for bringing this issue to our attention in the manuscript. In metabolic research, C57BL/6 mice are more commonly utilized as a model organism than BALC/c mice indeed. In this study we try to elucidate a characteristic may be shared among different mammalian species, namely the ability to produce a substantial amount of acetate during energy crises. However, given the constraints of our experimental setup, we opted to employ C57BL/6 mice as the main animal model to investigate the underlying mechanism. BALC/c mice were used to confirm the underlying mechanisms governing acetic acid production.
• In the experiments where ACOT8 and ACOT12 are selectively knocked out or knocked down, please include the levels of other ketone bodies, such as 3-HB and AcAC, from these experiments. While acetate production is diminished, there might or might not be a compensatory increase in the production of these metabolites. This would include experiments related to Figures 3, 4, and 5.
Thank you for your valuable comments. As you mentioned, in diabetic mice where ACOT12 and ACOT8 are knocked down in liver, there is a significant down-regulation of 3-HB and AcAc (Figure 7B, C). Based on this observation, we hypothesize that ACOT12 and ACOT8 might also play a regulatory role in the formation and metabolism of ketone bodies during an energy crisis. However, the precise regulatory mechanism underlying this phenomenon requires further investigation.
• From Figure 1 (source data 1), two patients with diabetes have concurrent cancer. Cancer cells have altered metabolism compared to native cells. Thus, it is possible that circulating acetate cells may be altered in these cancer patients, regardless of the presence of diabetes. This should be acknowledged. Otherwise, these two subjects should be taken out.
Thank you for your suggestions. We have taken out these two subjects in our revised manuscript.
• Can the authors expand on their thoughts on why some results from the behavioral tests are statistically significant while others are not? For example, many motor tasks such as forelimb strength, running time, total distance, and total entries significantly differ with ACOT8 and ACOT12 knockdown. However, more anxiety-based measures such as time in open arms, correct alteration, and object recognition are not statistically different.
Thank you for your comments. The evaluation of anxiety-related behavior is commonly done using the Elevated Plus Maze Test (EPMT), while working memory and cognitive functions are assessed through the Y-maze Test (YMZT) and Novel Object Recognition (NOR) Test. Measures such as forelimb strength and running time in the rotarod test, total distance in YMZT, total entries in YMZT and total distance in the NOR test are indicators of muscle force and movement ability. Our data demonstrate that acetate plays a significant role in enhancing muscle force and facilitating coordinated neuromuscular movement. Interestingly, we found that ACOT12/8 knockdown in the early stages of diabetes mellitus does not have a pronounced impact on psychiatric, memory, and cognitive behaviors (Figure 8 and figure supplement 2). However, it is important to note that our study primarily focuses on elucidating the utilization of acetate during energy crises, such as untreated diabetes and chronic hunger. Our findings suggest that acetate is primarily utilized to enhance motor capacity rather than cognitive or neural activity.
https://doi.org/10.7554/eLife.87419.3.sa4Article and author information
Author details
Funding
National Natural Science Foundation of China (U21A20373)
- Qinxi Li
National Natural Science Foundation of China (91857102)
- Qinxi Li
National Natural Science Foundation of China (31701252)
- Bin Jiang
National Natural Science Foundation of China (32100601)
- Huanhuan Ma
Open Research Fund of State Key Laboratory of Cellular Stress Biology (SKLCSB2020KF002)
- Qinxi Li
Open Research Fund of State Key Laboratory of Cellular Stress Biology (SKLCSB2019KF005)
- Qinxi Li
The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.
Acknowledgements
We thank members of the Qinxi Li’s laboratory for productive discussions and comments on this manuscript. We thank the Center of Major Equipment and Technology (COMET), State Key Laboratory of Marine Environmental Science (Xiamen University) for technical support.
Ethics
This study was approved by the Clinical Research Ethics Committee of the First Affiliated Hospital of Xiamen University (Xiamen, Fujian, China). Before clinical serum samples acquisition, written informed consent was obtained from each patient according to the policies of the committee.
All animal studies were approved by the Animal Ethics Committee of Xiamen University (China) (acceptance no: XMULAC20190166). All surgery was performed under sodium pentobarbital anesthesia, and every effort was made to minimize suffering.
Senior Editor
- Pramod K Mistry, Yale University, United States
Reviewing Editor
- Christoph Buettner, Rutgers Robert Wood Johnson Medical School, United States
Version history
- Preprint posted: March 23, 2023 (view preprint)
- Sent for peer review: March 23, 2023
- Preprint posted: June 20, 2023 (view preprint)
- Preprint posted: September 15, 2023 (view preprint)
- Version of Record published: October 30, 2023 (version 1)
Cite all versions
You can cite all versions using the DOI https://doi.org/10.7554/eLife.87419. This DOI represents all versions, and will always resolve to the latest one.
Copyright
© 2023, Wang, Wen, Zhao et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 305
- Page views
-
- 70
- Downloads
-
- 0
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Biochemistry and Chemical Biology
- Microbiology and Infectious Disease
An imbalance of the gut microbiota, termed dysbiosis, has a substantial impact on host physiology. However, the mechanism by which host deals with gut dysbiosis to maintain fitness remains largely unknown. In Caenorhabditis elegans, Escherichia coli, which is its bacterial diet, proliferates in its intestinal lumen during aging. Here, we demonstrate that progressive intestinal proliferation of E. coli activates the transcription factor DAF-16, which is required for maintenance of longevity and organismal fitness in worms with age. DAF-16 up-regulates two lysozymes lys-7 and lys-8, thus limiting the bacterial accumulation in the gut of worms during aging. During dysbiosis, the levels of indole produced by E. coli are increased in worms. Indole is involved in the activation of DAF-16 by TRPA-1 in neurons of worms. Our finding demonstrates that indole functions as a microbial signal of gut dysbiosis to promote fitness of the host.
-
- Biochemistry and Chemical Biology
- Structural Biology and Molecular Biophysics
The Neuronal Calcium Sensor 1, an EF-hand Ca2+ binding protein, and Ric-8A coregulate synapse number and probability of neurotransmitter release. Recently, the structures of Ric-8A bound to Ga have revealed how Ric-8A phosphorylation promotes Ga recognition and activity as a chaperone and guanine nucleotide exchange factor. However, the molecular mechanism by which NCS-1 regulates Ric-8A activity and its interaction with Ga subunits is not well understood. Given the interest in the NCS-1/Ric-8A complex as a therapeutic target in nervous system disorders, it is necessary to shed light on this molecular mechanism of action at atomic level. We have reconstituted NCS-1/Ric-8A complexes to conduct a multimodal approach and determine the sequence of Ca2+ signals and phosphorylation events that promote the interaction of Ric-8A with Ga. Our data show that the binding of NCS-1 and Ga to Ric-8A are mutually exclusive. Importantly, NCS-1 induces a structural rearrangement in Ric-8A that traps the protein in a conformational state that is inaccessible to Casein Kinase II-mediated phosphorylation, demonstrating one aspect of its negative regulation of Ric-8A-mediated G-protein signaling. Functional experiments indicate a loss of Ric-8A GEF activity towards Ga when complexed with NCS-1, and restoration of nucleotide exchange activity upon increasing Ca2+ concentration. Finally, the high-resolution crystallographic data reported here define the NCS-1/Ric-8A interface and will allow the development of therapeutic synapse function regulators with improved activity and selectivity.